Peptide RX

back to claim graph

proof receipt / target

MTOR

Mechanistic target of rapamycin

grade B status longevity receipt 225b05a4d8ba proof 33%

what this node claims

MTOR

Mechanistic target of rapamycin

Open source surface

vertical proof spine

  1. 01 MTOR target / grade B / 70% 1 debt
  2. 02 MTOR WT fold / grade B / 62% 2 debt

evidence / risk instrument

44%
thin proof
structure evidence gates risk export lineage 44
low debt pressure 21%
28%structuredebt
pLDDT pending
78%evidenceusable
grade B
0%gatesdebt
0/5 gates
100%riskstrong
0 hard flags
22%exportdebt
no export
33%lineagedebt
incomplete spine

proof completeness

33% missing alphafold_metric, candidate, finding, export
  1. 01 target
  2. 02 fold
  3. 03 alphafold metric
  4. 04 candidate
  5. 05 finding
  6. 06 export

Metrics and receipt inputs

binding partners
    context annotations
    0
    family
    kinase
    functional sites
      gene symbol
      MTOR
      go terms
        uniprot
        P42345

        AlphaFold metrics visual

        Confident backbone model

        78.0

        2549 residues / min 23.27 / max 94.56 / source alphafold db

        PAE matrix for linked target
        Very high 10.7% 272 residues / >=90
        Confident 71.5% 1822 residues / 70-89
        Low 8.0% 204 residues / 50-69
        Very low 9.8% 251 residues / <50

        usable fold context with explicit model-confidence limits

        Near-complete coverage / observed 2549 of 2549 residues.

        • residues 285-358 / mean 36.26
        • residues 2423-2494 / mean 40.7
        • residues 1811-1871 / mean 39.08
        • residues 1219-1260 / mean 49.55
        proof debt register

        Visible limits, not hidden cleanup.

        21%

        Peptide RX keeps unresolved proof debt attached to the public receipt. Some debts should be resolved; redaction and research-use boundaries should stay visible.

        medium missing functional-site annotations link target annotation, GO term, or binding-site context
        low computational-only status add independent evidence, challenge result, or witness review before strengthening
        medium no candidate yet leave visible until a stronger public receipt resolves it

        weakness and challenge edges

        What would stop this from becoming stronger.

        debt severity export claim strength next proof needed
        missing functional-site annotations medium visible weakens link target annotation, GO term, or binding-site context
        computational-only status low visible watch add independent evidence, challenge result, or witness review before strengthening
        no candidate yet medium visible weakens leave visible until a stronger public receipt resolves it

        what supports it

        No upstream proof edge yet.

        what it supports

        target has structure prediction target:b365223d-675f-4173-b5a9-b8938872ddd8 -> fold:63754d3c-0db9-433b-9610-6dd0157f9cb5 folds_to / B / 0.78

        Research-use boundary

        This receipt describes public computational research state. It does not expose raw candidate sequences and does not make a clinical claim.